These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 7838899

  • 21. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ, Harmatz JS, Shader RI.
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [Abstract] [Full Text] [Related]

  • 22. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
    O'Sullivan GH, Noshirvani H, Başoğlu M, Marks IM, Swinson R, Kuch K, Kirby M.
    Br J Psychiatry; 1994 Jul; 165(1):79-86. PubMed ID: 7802851
    [Abstract] [Full Text] [Related]

  • 23. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
    Sheehan DV, Sheehan KH, Raj BA.
    Psychopharmacol Bull; 2007 Jul; 40(2):63-81. PubMed ID: 17514187
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R.
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Anxiogenic properties of a computer simulation for panic disorder with agoraphobia.
    Freire RC, De Carvalho MR, Joffily M, Zin WA, Nardi AE.
    J Affect Disord; 2010 Sep; 125(1-3):301-6. PubMed ID: 20100626
    [Abstract] [Full Text] [Related]

  • 28. Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients.
    van Megen HJ, Westenberg HG, den Boer JA.
    Biol Psychiatry; 1996 Oct 15; 40(8):804-6. PubMed ID: 8894076
    [No Abstract] [Full Text] [Related]

  • 29. Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.
    Fukuda M, Takazawa S, Nakagome K, Iwanami A, Hata A, Kasai K, Hiramatsu K.
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Jul 15; 22(5):909-15. PubMed ID: 9723127
    [Abstract] [Full Text] [Related]

  • 30. The use of the Panic and Agoraphobia Scale in a clinical trial.
    Bandelow B, Brunner E, Broocks A, Beinroth D, Hajak G, Pralle L, Rüther E.
    Psychiatry Res; 1998 Jan 16; 77(1):43-9. PubMed ID: 10710174
    [Abstract] [Full Text] [Related]

  • 31. Treatment of panic disorder.
    Cassano GB, Toni C, Musetti L.
    Adv Biochem Psychopharmacol; 1992 Jan 16; 47():449-60. PubMed ID: 1509926
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ondansetron in the treatment of panic disorder.
    Schneier FR, Garfinkel R, Kennedy B, Campeas R, Fallon B, Marshall R, O'Donnell L, Hogan T, Liebowitz MR.
    Anxiety; 1996 Jan 16; 2(4):199-202. PubMed ID: 9160623
    [No Abstract] [Full Text] [Related]

  • 34. A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia.
    Inoue K, Kaiya H, Hara N, Okazaki Y.
    Compr Psychiatry; 2016 Aug 16; 69():132-5. PubMed ID: 27423353
    [Abstract] [Full Text] [Related]

  • 35. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology.
    Abelson JL, Nesse RM, Vinik AI.
    Biol Psychiatry; 1994 Jul 15; 36(2):84-96. PubMed ID: 7524696
    [Abstract] [Full Text] [Related]

  • 36. Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder.
    Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC.
    Biol Psychiatry; 1992 Jul 01; 32(1):18-25. PubMed ID: 1391293
    [Abstract] [Full Text] [Related]

  • 37. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
    Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P.
    J Affect Disord; 1995 Dec 13; 35(3):117-23. PubMed ID: 8749839
    [Abstract] [Full Text] [Related]

  • 38. Electrodermal activity in anxiety disorders.
    Birket-Smith M, Hasle N, Jensen HH.
    Acta Psychiatr Scand; 1993 Nov 13; 88(5):350-5. PubMed ID: 8296577
    [Abstract] [Full Text] [Related]

  • 39. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder.
    Kellner M, Yassouridis A, Jahn H, Wiedemann K.
    Psychopharmacology (Berl); 1997 Sep 13; 133(1):55-61. PubMed ID: 9335081
    [Abstract] [Full Text] [Related]

  • 40. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.
    Depress Anxiety; 2007 Sep 13; 24(1):1-14. PubMed ID: 16894619
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.